NCT00419081View on ClinicalTrials.gov

Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens

PHASE2TerminatedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
LeukemiaLymphoma
Interventions
DRUG

Forodesine Hydrochloride Sterile Solution, 5 mg/mL

DRUG

Forodesine Hydrochloride Capsules (100 mg)

Trial Locations (5)

10595

New York Medical College Division of Oncology, Valhalla

29203

Liberty Hematology and Oncology, Columbia

60637

University of Chicago Medical Center, Chicago

71103

Louisana State University Health Sciences Center, Shreveport

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY

NCT00419081 - Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens | Biotech Hunter | Biotech Hunter